Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Department of Pathology, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Histopathology. 2021 Jun;78(7):1019-1031. doi: 10.1111/his.14320. Epub 2021 Apr 10.
Papillary renal neoplasm with reverse polarity (PRNRP) is a newly defined entity with distinct histomorphology and recurrent KRAS mutation. It has been estimated to constitute 4% of previously diagnosed papillary renal cell carcinoma (PRCC). Renal papillary adenoma (PA) is suggested to be the precursor of PRCC. This study aimed to investigate the association between PRNRP and PA, particularly the morphologically similar type D PA.
Nephrectomy specimens of PRCC and PA from our 10-year pathology archives were retrieved and reviewed. GATA3 immunohistochemistry and RAS/BRAF testing were performed in all cases reclassified as PRNRP and all PAs with sufficient materials. Overall, PRNRP accounted for 9.1% (10 of 110) of PRCC and there was no recurrence/metastasis with a mean follow-up period of 39 months. Three novel morphological features were described, including clear cell change, mast cell infiltration and metaplastic ossification. Nine of the 10 PRNRPs showed diffuse and strong GATA3 expression and KRAS missense mutations at codon 12. One case exhibited moderate GATA3 staining on 80% of the tumour cells and RAS/BRAF wild-type. In a total of 73 PAs, 11 were classified as type D. GATA3 expression was significantly more frequent in type D versus non-type D PAs (100 versus 35%, P < 0.01). KRAS missense mutations were identified in six of eight (75%) of the type D PAs but none of the 18 non-type D PAs.
Type D PA was different from other types of PA and represented an analogue or a small-sized PRNRP for their identical morphology, immunophenotype and molecular signature.
具有反向极性的乳头状肾肿瘤(PRNRP)是一种具有独特组织形态学和复发性 KRAS 突变的新定义实体。据估计,它构成了先前诊断为乳头状肾细胞癌(PRCC)的 4%。肾乳头状腺瘤(PA)被认为是 PRCC 的前体。本研究旨在探讨 PRNRP 与 PA 之间的关系,特别是形态相似的 D 型 PA。
从我们 10 年的病理档案中检索并回顾了 PRCC 和 PA 的肾切除术标本。对所有重新分类为 PRNRP 的病例和所有有足够材料的 D 型 PA 进行 GATA3 免疫组化和 RAS/BRAF 检测。总体而言,PRNRP 占 PRCC 的 9.1%(110 例中的 10 例),在平均 39 个月的随访期间没有复发/转移。描述了三个新的形态学特征,包括透明细胞改变、肥大细胞浸润和化生性骨化。10 例 PRNRP 中有 9 例表现出弥漫性和强 GATA3 表达以及 KRAS 密码子 12 的错义突变。1 例肿瘤细胞的 80%显示中度 GATA3 染色,RAS/BRAF 野生型。在总共 73 例 PA 中,有 11 例被分类为 D 型。D 型与非 D 型 PA 相比,GATA3 表达明显更为频繁(100%对 35%,P<0.01)。在 8 例 D 型 PA 中有 6 例发现 KRAS 错义突变,但在 18 例非 D 型 PA 中均未发现。
D 型 PA 与其他类型的 PA 不同,它们具有相同的形态、免疫表型和分子特征,代表了模拟物或小型 PRNRP。